Minerva Surgical, Inc. (UTRS)
Company Description
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States.
The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.
Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices.
The company was incorporated in 2008 and is headquartered in Santa Clara, California.
| Country | United States |
| Founded | 2008 |
| IPO Date | Oct 22, 2021 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 157 |
| CEO | Mr. David M. Clapper |
Contact Details
Address:
4255 Burton Drive Santa Clara, California 95054 United States | |
| Phone | (855) 646-7874 |
| Website | minervasurgical.com |
Stock Details
| Ticker Symbol | UTRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001452965 |
| CUSIP Number | 60343F106 |
| ISIN Number | US60343F1066 |
| Employer ID | 26-3422906 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David M. Clapper | President, Chief Executive Officer and Director |
| Joel R. Jung MBA | Chief Financial Officer |
| Dominique J. Filloux | Chief Operating Officer |
| Thomas Pendlebury | Vice President of Sales and Marketing |
| Wendy Bowman | Vice President of Human Resources |
| Joanne Long | Vice President of Corporate Controller |
| Dr. Evgueni V. Skalnyi M.D. | Vice President of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 24, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 23, 2023 | DEF 14A | Other definitive proxy statements |
| Jan 17, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 17, 2023 | 8-K | Current Report |
| Jan 13, 2023 | PRE 14A | Other preliminary proxy statements |
| Dec 30, 2022 | 8-K | Current Report |
| Dec 28, 2022 | 8-K | Current Report |
| Dec 28, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 28, 2022 | 8-K | Current Report |
| Nov 16, 2022 | 8-K/A | [Amend] Current report |